Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA). [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating pharmacokinetics, pharmacodynamics, and safety of Tocilizumab in Giant Cell Arteritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Giant Cell Arteritis | Phase 1 | Status: COMPLETED | Results posted: 2021-12-22